Andrew Dillon

Showing 4 posts of 4 posts found.

Benlysta image

NICE no to GSK’s lupus drug Benlysta

April 27, 2012
Sales and Marketing Andrew Dillon, Benlysta, GSK, Lupus, NICE

NICE is still not recommending GlaxoSmithKline’s lupus drug Benlysta, as it believes the treatment is too costly.  In its final …

Change is needed, concedes NICE chief, but defends record

November 30, 2010
Sales and Marketing Andrew Dillon, NHS reform, NICE, cost-effectiveness, health technology assessment, hta, value-based pricing

The chief executive of NICE acknowledges changes are needed in how drugs are assessed in the UK – including more …

NICE ‘surprised’ at downgrading of its role

November 5, 2010
Sales and Marketing Andrew Dillon, GP prescribing deicisions, NICE, QALY, incremental cost-effectiveness ratio, value-based pricing

NICE received no warning that its health technology assessment role is to be downgraded, the watchdog’s head has admitted. In …

Andrew-Dillon

NICE chief executive knighted in New Year’s honours

January 6, 2010
Andrew Dillon, NHS, NICE, UK, appointment

Andrew Dillon, chief executive of the National Institute for Health and Clinical Excellence (NICE), has been knighted in the 2010 …

The Gateway to Local Adoption Series

Latest content